DOV-216,303

From Wikipedia, the free encyclopedia
Jump to: navigation, search
DOV-216,303
DOV-216,303.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C11H11Cl2N
Molar mass 228.117 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and Dov terminated their relationship in December 2006.[2]:12[3]

It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]

As of March 2008, Dov had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]:6

See also[edit]

References[edit]

  1. ^ McCoy, Michael (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". C&EN. 
  2. ^ a b "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008. DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned. 
  3. ^ "DOV 216303". AdisInsight. Retrieved 26 February 2017. 
  4. ^ a b Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. (2006). "Preclinical and Clinical Pharmacology of DOV 216,303, a "Triple" Reuptake Inhibitor". CNS Drug Reviews. 12 (2): 123–134. PMID 16958986. doi:10.1111/j.1527-3458.2006.00123.x.